163 related articles for article (PubMed ID: 14765735)
1. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs.
Kristal O; Rassnick KM; Gliatto JM; Northrup NC; Chretin JD; Morrison-Collister K; Cotter SM; Moore AS
J Vet Intern Med; 2004; 18(1):75-80. PubMed ID: 14765735
[TBL] [Abstract][Full Text] [Related]
2. Low apparent risk of CCNU (lomustine)-associated clinical hepatotoxicity in cats.
Musser ML; Quinn HT; Chretin JD
J Feline Med Surg; 2012 Dec; 14(12):871-5. PubMed ID: 22772480
[TBL] [Abstract][Full Text] [Related]
3. CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).
Heading KL; Brockley LK; Bennett PF
Aust Vet J; 2011 Apr; 89(4):109-16. PubMed ID: 21418164
[TBL] [Abstract][Full Text] [Related]
4. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs.
Moore AS; London CA; Wood CA; Williams LE; Cotter SM; L'Heureux DA; Frimberger AE
J Vet Intern Med; 1999; 13(5):395-8. PubMed ID: 10499719
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of elevated alanine transaminase activity in dogs treated with CCNU (Lomustine)*.
Hosoya K; Lord LK; Lara-Garcia A; Kisseberth WC; London CA; Couto CG
Vet Comp Oncol; 2009 Dec; 7(4):244-55. PubMed ID: 19891695
[TBL] [Abstract][Full Text] [Related]
6. Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma.
Rassnick KM; Bailey DB; Malone EK; Flory AB; Kiselow MA; Intile JL
J Am Anim Hosp Assoc; 2014; 50(3):167-73. PubMed ID: 24659727
[TBL] [Abstract][Full Text] [Related]
7. Treatment of canine mast cell tumors with CCNU (lomustine).
Rassnick KM; Moore AS; Williams LE; London CA; Kintzer PP; Engler SJ; Cotter SM
J Vet Intern Med; 1999; 13(6):601-5. PubMed ID: 10587263
[TBL] [Abstract][Full Text] [Related]
8. CCNU in the treatment of canine epitheliotropic lymphoma.
Williams LE; Rassnick KM; Power HT; Lana SE; Morrison-Collister KE; Hansen K; Johnson JL
J Vet Intern Med; 2006; 20(1):136-43. PubMed ID: 16496933
[TBL] [Abstract][Full Text] [Related]
9. Risk factors associated with the onset of lomustine-induced neutropenia in tumour-bearing dogs.
Treggiari E; Cossu G; Valenti P; Taylor A
Vet Comp Oncol; 2022 Sep; 20(3):577-586. PubMed ID: 35249267
[TBL] [Abstract][Full Text] [Related]
10. Prospective randomized clinical trial assessing the efficacy of Denamarin for prevention of CCNU-induced hepatopathy in tumor-bearing dogs.
Skorupski KA; Hammond GM; Irish AM; Kent MS; Guerrero TA; Rodriguez CO; Griffin DW
J Vet Intern Med; 2011; 25(4):838-45. PubMed ID: 21689156
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors.
Hosoya K; Kisseberth WC; Alvarez FJ; Lara-Garcia A; Beamer G; Stromberg PC; Couto CG
J Am Anim Hosp Assoc; 2009; 45(1):14-8. PubMed ID: 19122059
[TBL] [Abstract][Full Text] [Related]
12. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
[TBL] [Abstract][Full Text] [Related]
13. Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): a retrospective study of 46 cases (1999-2004).
Risbon RE; de Lorimier LP; Skorupski K; Burgess KE; Bergman PJ; Carreras J; Hahn K; Leblanc A; Turek M; Impellizeri J; Fred R; Wojcieszyn JW; Drobatz K; Clifford CA
J Vet Intern Med; 2006; 20(6):1389-97. PubMed ID: 17186855
[TBL] [Abstract][Full Text] [Related]
14. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs.
Flory AB; Rassnick KM; Al-Sarraf R; Bailey DB; Balkman CE; Kiselow MA; Autio K
J Vet Intern Med; 2008; 22(1):164-71. PubMed ID: 18289305
[TBL] [Abstract][Full Text] [Related]
15. Phase I evaluation of CCNU (lomustine) in tumor-bearing cats.
Rassnick KM; Gieger TL; Williams LE; Ruslander DM; Northrup NC; Kristal O; Myers NC; Moore AS
J Vet Intern Med; 2001; 15(3):196-9. PubMed ID: 11380027
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of metronomic administration of lomustine in dogs with cancer.
Tripp CD; Fidel J; Anderson CL; Patrick M; Pratt C; Sellon R; Bryan JN
J Vet Intern Med; 2011; 25(2):278-84. PubMed ID: 21314727
[TBL] [Abstract][Full Text] [Related]
17. Lipid association improves the therapeutic index of lomustine [1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea] to suppress 36B-10 tumor growth in rats.
Bethune CR; Geyer RJ; Spence AM; Ho RJ
Cancer Res; 2001 May; 61(9):3669-74. PubMed ID: 11325837
[TBL] [Abstract][Full Text] [Related]
18. Is CCNU (lomustine) valuable for treatment of cutaneous epitheliotropic lymphoma in dogs? A critically appraised topic.
Laprais A; Olivry T
BMC Vet Res; 2017 Feb; 13(1):61. PubMed ID: 28222789
[TBL] [Abstract][Full Text] [Related]
19. Methyl-CCNU: preclinical toxicologic evaluation of a single iv infusion in dogs and monkeys.
Schaeppi U; Fleischman RW; Phelan RS; Ethier MF; Luthra YK
Cancer Treat Rep; 1976 Oct; 60(10):1559-66. PubMed ID: 828519
[TBL] [Abstract][Full Text] [Related]
20. CCNU for the treatment of dogs with histiocytic sarcoma.
Skorupski KA; Clifford CA; Paoloni MC; Lara-Garcia A; Barber L; Kent MS; LeBlanc AK; Sabhlok A; Mauldin EA; Shofer FS; Couto CG; Sørenmo KU
J Vet Intern Med; 2007; 21(1):121-6. PubMed ID: 17338159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
